SOCS6抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Jurkat, 293T, Hela cell, Mouse liver tissue lysates, Primary antibody: P00695(SOCS6 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P00695(SOCS6 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P00695(SOCS6 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The suppressor of cytokine signaling 6 (SOCS6) antibody is a research tool used to detect and study the SOCS6 protein, a member of the SOCS family involved in regulating cellular signaling pathways. SOCS6 acts as a negative regulator of cytokine and growth factor signaling, primarily by targeting specific receptors or kinases for ubiquitination and proteasomal degradation. It plays roles in insulin signaling, cell proliferation, and apoptosis, with implications in cancer, metabolic disorders, and immune responses. The SOCS6 antibody is essential for investigating its expression patterns, subcellular localization, and interactions in various biological contexts.

SOCS6 antibodies are typically developed against specific epitopes, such as the N-terminal or C-terminal regions, and are validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. They help identify SOCS6's involvement in diseases; for example, reduced SOCS6 expression is linked to tumor progression in certain cancers, while its overexpression may suppress oncogenic pathways. Researchers also use these antibodies to explore SOCS6's regulatory mechanisms, including its SH2 domain-mediated binding to phosphorylated targets and SOCS box-dependent E3 ubiquitin ligase activity.

Species reactivity (human, mouse, rat) and validation in knock-out models are critical considerations. Dysregulation of SOCS6 has been associated with pathologies like hepatocellular carcinoma and diabetes, making its antibody a valuable tool for both basic research and therapeutic target discovery.